|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2008-5-21
|
|
pubmed:abstractText |
In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues, kidney uptake of radiolabelled compound is the major dose-limiting factor. We studied the effects of Gelofusine (20 mg) and lysine (100 mg) and the combination of both after injection of therapeutic doses of radiolabelled [DOTA0,Tyr3]octreotate (60 MBq 111In or 555 MBq 177Lu labelled to 15 microg peptide) in male Lewis rats.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0029-5566
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
47
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
110-5
|
|
pubmed:meshHeading |
pubmed-meshheading:18493690-Animals,
pubmed-meshheading:18493690-Biological Transport,
pubmed-meshheading:18493690-Drug Hypersensitivity,
pubmed-meshheading:18493690-Humans,
pubmed-meshheading:18493690-Kidney,
pubmed-meshheading:18493690-Lutetium,
pubmed-meshheading:18493690-Lysine,
pubmed-meshheading:18493690-Octreotide,
pubmed-meshheading:18493690-Organometallic Compounds,
pubmed-meshheading:18493690-Polygeline,
pubmed-meshheading:18493690-Radioisotopes,
pubmed-meshheading:18493690-Rats,
pubmed-meshheading:18493690-Tomography, Emission-Computed, Single-Photon
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Molecular imaging of reduced renal uptake of radiolabelled [DOTA0,Tyr3]octreotate by the combination of lysine and Gelofusine in rats.
|
|
pubmed:affiliation |
Department Nuclear Medicine, Room L244, Erasmus MC's Gravendijkwal 230, 3015 CE Rotterdam, The Netherlands. e.rolleman@erasmusmc.nl
|
|
pubmed:publicationType |
Journal Article
|
